1. Exploratory cost-effectiveness analysis of 68 Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer.
- Author
-
Gordon LG, Elliott TM, Joshi A, Williams ED, and Vela I
- Subjects
- Adult, Androgen Antagonists therapeutic use, Australia epidemiology, Chemoradiotherapy, Adjuvant, Clinical Decision-Making methods, Cost Savings, Disease-Free Survival, Gallium Isotopes, Gallium Radioisotopes, Health Care Costs statistics & numerical data, Humans, Kallikreins blood, Magnetic Resonance Imaging methods, Male, Membrane Glycoproteins, Multimodal Imaging methods, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local therapy, Organometallic Compounds, Pilot Projects, Positron Emission Tomography Computed Tomography methods, Progression-Free Survival, Prostate diagnostic imaging, Prostate pathology, Prostate surgery, Prostate-Specific Antigen blood, Prostatectomy methods, Prostatic Neoplasms blood, Prostatic Neoplasms mortality, Prostatic Neoplasms therapy, Quality-Adjusted Life Years, Sensitivity and Specificity, Cost-Benefit Analysis, Magnetic Resonance Imaging economics, Multimodal Imaging economics, Neoplasm Recurrence, Local diagnosis, Positron Emission Tomography Computed Tomography economics, Prostatic Neoplasms diagnosis
- Abstract
Men treated for prostate cancer with curative intent face a recurrence rate of up to 53% at 10 years.
68 Ga-PSMA imaging is a new technique that can more accurately stage cancer recurrences and facilitate personalised treatment. We evaluated the cost-effectiveness of68 Ga-PSMA PET/MRI for staging men with prostate cancer biochemical recurrence. A cost-effectiveness analysis using a decision-analytic model with Markov chains was constructed.68 Ga-PSMA PET/MRI was compared with usual care in staging of men with suspected prostate cancer recurrence. Men with biochemical recurrence from a study in Brisbane, Australia (n = 30) provided key estimates for the model. The primary outcomes were health system costs and years of life (survival) over 10 years. Deterministic and probabilistic sensitivity analyses were undertaken to address uncertainty in model estimates. On average, a strategy of68 Ga-PSMA was expected to cost AU$56 961(US$39 426) and produce 7.48 life years compared with AU$64 499 (US$44 667) and 7.41 life years in usual care. Therefore,68 Ga-PSMA was potentially cost saving (- AU$7 592 95% UI - $24 846, $7 825) (- US$5 258) and slightly more effective 0.07 life years (95% UI - 0.01, 0.16). The likelihood that68 Ga-PSMA strategy was cost-effective at acceptable thresholds was 87%. The findings were sensitive to the lesion detection rate of the68 Ga-PSMA strategy (52-75%) and the cost of follow up in usual care (AU$1 947 to $2 635). In this exploratory economic evaluation, using68 Ga-PSMA PET/MRI to detect prostate cancer recurrence appears to be cost-effective relative to usual care.- Published
- 2020
- Full Text
- View/download PDF